Immune Pharmaceuticals To Expand Bullous Pemphigoid Clinical Development Plan For Bertilimumab

Loading...
Loading...
Immune Pharmaceuticals Inc. ("Immune", the "Company")
IMNP
announced today that it intends to expand its planned bullous pemphigoid (BP) clinical development for bertilimumab, a fully human monoclonal antibody targeting eotaxin-1. Bullous Pemphigoid is an orphan auto-immune blistering disease of the skin affecting approximately 60,000 patients in the US and Europe. As previously announced, Immune expects to start enrolling patients in a Phase II clinical trial in Israel to be treated during the second quarter of 2015. Additionally, following an International Medical Advisory Board meeting held in San Francisco immediately prior to the American Academy of Dermatology annual meeting, Immune has decided to expand its clinical program to include US centers in the Phase II BP development program. The Company also intends to initiate studies to further investigate the relationship between eotaxin-1 levels and the Bullous Pemphigoid Disease Area Activity Index (BPDAI) and to assess the burden of illness from a medical and economic standpoint. Immune has formed an International Medical Advisory Board for the development of Bertilimumab in BP, with Key Opinion Leaders including Professor Neil Korman (Case Western, Cleveland, USA), Professor Russell Hall (Duke University, USA), Professor Pascal Joly (Rouen, France) and Professor Dedee Murrell (Sydney, Australia). "Immune Pharmaceuticals is committed to better understanding this orphan disease and improving clinical outcomes and quality of life for patients with Bullous Pemphigoid and other auto-immune diseases," said Dr. Daniel Teper, CEO of Immune Pharmaceuticals.
Loading...
Loading...
Posted In: NewsFDAPress Releases
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...